Recent studies have reported that treatment with anti–PD-1 and anti–CTLA-4 antibodies is an effective therapeutic option for patients with HNSCC (Italiano et al., 2021; Mao et al., 2021; Qin et al., 2021). This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.